Brief Report - (2023) Volume 14, Issue 5
Received: 02-Oct-2023, Manuscript No. jmbd-23-117213;
Editor assigned: 04-Oct-2023, Pre QC No. P-117213;
Reviewed: 16-Oct-2023, QC No. Q-117213;
Revised: 23-Oct-2023, Manuscript No. R-117213;
Published:
30-Oct-2023
, DOI: 10.37421/2155-9929.2023.14.595
Citation: Lee, Zaira. “A Review of MicroRNA (miRNA) Research
in Glaucoma.” J Mol Biomark Diagn 14 (2023): 595.
Copyright: © 2023 Lee Z. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Glaucoma, a group of progressive optic neuropathies, is a leading cause of irreversible blindness worldwide. This complex ocular disorder is characterized by the degeneration of retinal ganglion cells, resulting in characteristic visual field defects. Despite advances in glaucoma research and management, early detection and effective therapeutic interventions remain challenging [1]. In recent years, MicroRNAs (miRNAs) have garnered significant attention as potential key players in the pathogenesis of glaucoma. MiRNAs are small, noncoding RNA molecules that post-transcriptionally regulate gene expression and their dysregulation has been implicated in various diseases, including glaucoma. The aim of this review is to provide an overview of the growing body of miRNA research in the context of glaucoma, with a focus on their diagnostic and therapeutic potential. By exploring the intricate roles of miRNAs in glaucoma pathophysiology and their relevance as biomarkers or therapeutic targets, this review underscores the promising implications of miRNA studies in advancing our understanding and management of this sight-threatening condition [2,3].
MiRNAs are emerging as important regulators of gene expression in glaucoma. Numerous studies have identified altered miRNA profiles in the ocular tissues of glaucoma patients, suggesting their involvement in disease pathogenesis. MiRNAs are known to influence various cellular processes, such as apoptosis, oxidative stress and inflammation, all of which are intricately linked to glaucomatous damage [4]. Furthermore, miRNAs can be detected in various ocular fluids, making them attractive candidates for noninvasive diagnostic biomarkers. Researchers have explored the diagnostic potential of miRNAs to distinguish glaucoma patients from healthy individuals or to differentiate between glaucoma subtypes. Additionally, investigations into the therapeutic role of miRNAs in glaucoma have opened exciting avenues. Modulating miRNA expression levels offers the potential to mitigate pathological processes and preserve retinal ganglion cell function. However, the translation of miRNA research into clinical practice requires further validation and standardization [5].
In conclusion, miRNA studies in glaucoma present a compelling and rapidly evolving area of research with significant diagnostic and therapeutic promise. The dysregulation of miRNAs in glaucoma pathophysiology is becoming increasingly evident, shedding light on their roles in retinal ganglion cell degeneration. Moreover, the diagnostic potential of miRNAs as non-invasive biomarkers offers hope for early glaucoma detection and personalized patient care. The therapeutic implications are equally exciting, with the potential to develop miRNA-based interventions that target specific pathways implicated in glaucomatous damage. Nonetheless, it is essential to acknowledge that further research, clinical validation and standardization are needed before miRNA-based approaches become integral to glaucoma management. As our understanding of miRNAs' roles in glaucoma continues to expand, they hold the promise of playing a pivotal role in enhancing our ability to diagnose, monitor and treat this sight-threatening condition.
None.
There are no conflicts of interest by author.
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
